Skip to main content
Midas Edge

Denali Therapeutics Inc.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

DNLI$19.85-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders' Equity
Shares · Amount
Balance at December 31, 2024144,220,986$1,768$2,764,880$2,020$(1,538,984)$1,229,684
Issuances under equity incentive plans455,33554,647——4,652
Vesting of restricted stock units1,009,12110(10)———
Stock-based compensation——50,887——50,887
Net loss————(257,089)(257,089)
Other comprehensive loss———(1,081)—(1,081)
Balance at June 30, 2025145,685,442$1,783$2,820,404$939$(1,796,073)$1,027,053
Balance at March 31, 2025145,251,258$1,778$2,790,825$2,037$(1,671,954)$1,122,686
Issuances under equity incentive plans341,54344,053——4,057
Vesting of restricted stock units92,6411(1)———
Stock-based compensation——25,527——25,527
Net loss————(124,119)(124,119)
Other comprehensive loss———(1,098)—(1,098)
Balance at June 30, 2025145,685,442$1,783$2,820,404$939$(1,796,073)$1,027,053
Balance at December 31, 2023138,385,498$1,711$2,144,811$643$(1,116,211)$1,030,954
Issuance of common stock and pre-funded warrants, net of issuance costs of $4803,244,68932499,221——499,253
Issuances under equity incentive plans657,52277,771——7,778
Vesting of restricted stock units835,8737(7)———
Stock-based compensation——53,196——53,196
Net loss————(200,828)(200,828)
Other comprehensive loss———(3,302)—(3,302)
Balance at June 30, 2024143,123,582$1,757$2,704,992$(2,659)$(1,317,039)$1,387,051
Balance at March 31, 2024142,512,856$1,751$2,673,033$(1,296)$(1,218,013)$1,455,475
Issuances under equity incentive plans527,30856,750——6,755
Vesting of restricted stock units83,4181(1)———
Stock-based compensation——25,210——25,210
Net loss————(99,026)(99,026)
Other comprehensive loss———(1,363)—(1,363)
Balance at June 30, 2024143,123,582$1,757$2,704,992$(2,659)$(1,317,039)$1,387,051
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.